AstraZeneca plans USD 2 billion manufacturing investment in Maryland

The two companies are entering into a strategic collaboration with the goal of developing next-generation solutions in preclinical drug development.

European life science VC firm Sofinnova Partners has announced the close of its latest flagship fund, Sofinnova Capital XI, at EUR 650 million (USD 750 million).

The collaboration includes process development and manufacturing of TIR-01, the active substance in TIRmed’s treatment for atopic dermatitis (eczema), and marks an important step towards future clinical trials.

As one of WHO’s official health campaigns, the World AMR Awareness Week (WAAW) is mandated by the World Health Assembly and is commemorated annually from 18 to 24 November.

Vicore Pharma Holding has completed a directed share issue through which the company raises gross proceeds of approximately USD 48 million (approximately SEK 455 million) before deduction of transaction costs.

Merck (known as MSD outside of the United States and Canada), and Cidara Therapeutics, a biotech company developing drug-Fc conjugate (DFC) therapeutics, have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for a total transaction value of approximately USD 9.2 billion.

Earlier this autumn the company announced a takeover offer to acquire all of the issued and outstanding shares in Bavarian Nordic by Innosera, a company controlled by Nordic Capital Fund XI and funds managed and advised by Permira Beteiligungsberatung. The offeror has now informed Bavarian Nordic that, as the minimum acceptance condition has not been satisfied, […]